<?xml version="1.0" encoding="UTF-8"?>
<p>3. An important finding of this study is current limitations on CHB research; ie the impact on location and genotype context on scores calculated from biomarkers, age, and fibrosis scores. Whether EASL, WHO, or TREAT-B are the most appropriate for this population is actually unknown. In addition, in all of these settings appropriate treatment duration and criteria for treatment discontinuation remain unclear.</p>
